Aurobindo Pharma gained approval for its ANDA208746 on June 24, 2026, introducing a generic version of the brand-name drug icosapent ethyl to the market. This regulatory clearance is expected to significantly increase market volume for the product, intensifying competition with the Crestor and Vascepa brands and driving downstream price erosion.